Eye scans could reveal hidden clues about MS drug effectiveness

NCT ID NCT06864936

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a special eye scan (OCT) can detect changes in the retina that show how well the MS drug ublituximab is working. Researchers will compare 15 people starting ublituximab with 15 people on other MS treatments. The goal is to find a new, non-invasive way to monitor treatment response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ublituximab

What this could lead to

If successful, this could lead to a new way to monitor MS treatment response using simple eye scans, potentially improving care.

What could go wrong

This is a small, early-stage study focused on biomarkers, not on proving the drug works. The new imaging method may not prove useful in practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) - RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Maryland, Baltimore

    RECRUITING

    Baltimore, Maryland, 21201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact